Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-cash Items (2017 - 2024)

Historic Non-cash Items for Coherus Oncology (CHRS) over the last 10 years, with Q4 2024 value amounting to $24.6 million.

  • Coherus Oncology's Non-cash Items fell 3422.46% to $24.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $24.6 million, marking a year-over-year decrease of 3422.46%. This contributed to the annual value of $24.6 million for FY2024, which is 3422.46% down from last year.
  • According to the latest figures from Q4 2024, Coherus Oncology's Non-cash Items is $24.6 million, which was down 3422.46% from $37.4 million recorded in Q4 2023.
  • Coherus Oncology's Non-cash Items' 5-year high stood at $72.4 billion during Q4 2020, with a 5-year trough of $24.6 million in Q4 2024.
  • For the 5-year period, Coherus Oncology's Non-cash Items averaged around $14.5 billion, with its median value being $51.5 million (2022).
  • Per our database at Business Quant, Coherus Oncology's Non-cash Items surged by 7711538.96% in 2020 and then plummeted by 9991.52% in 2021.
  • Over the past 5 years, Coherus Oncology's Non-cash Items (Quarter) stood at $72.4 billion in 2020, then tumbled by 99.92% to $61.4 million in 2021, then decreased by 16.12% to $51.5 million in 2022, then decreased by 27.38% to $37.4 million in 2023, then crashed by 34.22% to $24.6 million in 2024.
  • Its last three reported values are $24.6 million in Q4 2024, $37.4 million for Q4 2023, and $51.5 million during Q4 2022.